HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?

Shares of HUTCHMED (China) Limited (LON:HCM - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 229.27 and traded as low as GBX 211.09. HUTCHMED shares last traded at GBX 216, with a volume of 10,495 shares trading hands.HUTCHMED Stock PerformanceThe stock's 50-day moving average price is GBX 214 and its 200 day moving average price is GBX 229.27. The company has a quick ratio of 2.97, a current ratio of 2.81 and a debt-to-equity ratio of 11.97. The company has a market cap of £1.93 billion, a P/E ratio of 4.23 and a beta of 0.76. About HUTCHMED (Get Free Report)We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).Further ReadingFive stocks we like better than HUTCHMEDElon Taking SpaceX Public! $100 Pre-IPO Opportunity!Do not delete, read immediatelyThis stock gets a 94 out of 100Ticker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyExecutive Order 14330: Trump’s Biggest YetThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in HUTCHMED Right Now?Before you consider HUTCHMED, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here